← Back to Search

Other

Adagrasib + Eltrombopag Drug Interaction in Healthy Adults

Phase 1
Waitlist Available
Research Sponsored by Mirati Therapeutics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 1 and 8
Awards & highlights

Study Summary

This trial studies how one cancer medicine affects the body when taken with another medicine in healthy adults.

Who is the study for?
Healthy adults aged 18-60 with a BMI of 18.0 to 32.0 kg/m2 can join this trial. They must be in good health without significant medical issues, not pregnant or breastfeeding, and willing to use contraception. People with gastrointestinal conditions, drug allergies, serious diseases, recent drug abuse history or those using certain medications are excluded.Check my eligibility
What is being tested?
The study is testing how an inhibitor of the Breast Cancer Resistance Protein (BCRP) affects the body's handling of Adagrasib when taken together in healthy subjects. It's a Phase 1 trial where participants first take Adagrasib alone and then combined with Eltrombopag.See study design
What are the potential side effects?
As it's a Phase 1 trial primarily assessing safety and dosage levels, specific side effects aren't listed but may include reactions at the site of administration, general discomforts like headaches or nausea, and potential allergic reactions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 1 and 8
This trial's timeline: 3 weeks for screening, Varies for treatment, and days 1 and 8 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pharmacokinetics - AUC (adagrasib)
Pharmacokinetics - CL/F (adagrasib)
Pharmacokinetics - Cmax (adagrasib)
+3 more
Secondary outcome measures
Adverse Events (AEs)

Trial Design

2Treatment groups
Active Control
Group I: Treatment AActive Control1 Intervention
Treatment A: A single oral dose of adagrasib 400 mg (2 × 200-mg tablets) on Day 1;
Group II: Treatment BActive Control1 Intervention
Treatment B: A single oral dose of eltrombopag 75 mg (1 × 75-mg tablet) plus adagrasib 400 mg (2 × 200-mg tablets) on Day 8.

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Mirati Therapeutics Inc.Lead Sponsor
70 Previous Clinical Trials
8,239 Total Patients Enrolled
4 Trials studying Healthy Adults
105 Patients Enrolled for Healthy Adults

Media Library

Adagrasib (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05924152 — Phase 1
Healthy Adults Research Study Groups: Treatment A, Treatment B
Healthy Adults Clinical Trial 2023: Adagrasib Highlights & Side Effects. Trial Name: NCT05924152 — Phase 1
Adagrasib (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05924152 — Phase 1
Healthy Adults Patient Testimony for trial: Trial Name: NCT05924152 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this trial open to participants of all ages, or are there age restrictions?

"This investigation requires the recruitment of adults aged 18-60."

Answered by AI

What is the criteria for eligibility to participate in this clinical trial?

"This clinical trial is accepting 16 participants, each of which must be a healthy adult between the ages of 18 and 60."

Answered by AI

What is the risk profile of Treatment A for those being treated?

"Due to the lack of clinical data on Treatment A, our team at Power have assigned a safety rating of 1. This is indicative that it is currently in Phase 1 and there remains limited evidence for both efficacy and security."

Answered by AI

Is the patient population for this clinical trial still expanding?

"This medical experiment is not presently enrolling volunteers; its posting date was June 29th 2023 and the last recorded edit took place on June 20th of that same year. Nonetheless, there are 13 other studies actively recruiting patients at this time."

Answered by AI

Who else is applying?

What state do they live in?
New Mexico
Florida
What site did they apply to?
Fortrea Clinical Research Unit Daytona Beach (Labcorp Clinical Research Unit Daytona Beach)
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

Looking for paid studies.
PatientReceived 2+ prior treatments
Recent research and studies
clinicaltrials.govStudy
A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib
2023. "A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05924152.
~9 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top